GlaxoSmithKline: Shingles Treatment Meets Objective in Phase III Trial
June 21 2017 - 9:40AM
Dow Jones News
LONDON-- GlaxoSmithKline PLC (GSK.LN) Wednesday said a Phase III
study of its shingles vaccine Shingrix showed a strong immune
response in older adults, meeting its primary objective.
Shares at 1309GMT, down 13 pence, or 0.8%, at 1,680 pence
valuing the company at GBP82.62 billion
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
(END) Dow Jones Newswires
June 21, 2017 09:25 ET (13:25 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024